Iron oxide nanoparticle (IOP) injection has completed its animal testing and safety evaluation. It will enter its Phase I of the clinical trial, moving towards the goal of launching the product on the market. It is expected that the first type of medicine will be launched in 2018, providing chronic kidney disease patient with a fast and effective iron supplement.
